Harmonizing and improving network connectivity after a merger

The pharmaceutical industry is experiencing pressures on pricing, the cost of drug development, and changing business models. To combat this, there is strong M&A activity to achieve scale, savings, and diversification of portfolios in the biotech space. There are also industry-wide aggressive digital transformation programs, leveraging big data to lower costs and shorten production cycles.